Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
Phase 1 Completed
42 enrolled
3-AP and Cytarabine in Treating Patients With Hematologic Cancer
Phase 1 Completed
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
Phase 1 Completed
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
Phase 1/2 Completed
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders
Phase 1 Completed
25 enrolled
STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
Phase 1/2 Completed
46 enrolled
3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies
Phase 1 Completed
48 enrolled
Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia
Phase 2 Terminated
60 enrolled